<p>/PRNewswire/ -- 股东权益法律事务所 Johnson Fistel, PLLP 正在调查 Soleno Therapeutics, Inc. (NASDAQ: SLNO) 或其某些高管和董事是否违反了联邦证券法，通过发布虚假或误导性声明和/或未向投资者披露重要信息。</p>
<p>该调查还审查了 Soleno 的公开沟通是否准确反映了 VYKAT™ XR 在获得监管批准后的商业进展和安全性。</p>
<p>在 2025 年 9 月，FDA 批准 VYKAT™ XR 后，Soleno 向投资者强调该产品的推出表现强劲，超出了内部预期。</p>
<p>然而，在 Soleno 于 2025 年 11 月 4 日的第三季度财报电话会议上，公司讨论了在推出期间出现的挑战，指出新治疗启动的放缓以及与非严重不良事件相关的治疗中断增加。管理层还承认，推出轨迹受到了年初发布的外部评论的影响。</p>
<p>在 2025 年 8 月 15 日，做空机构 Scorpion Capital 发布了一份报告，提出了关于 VYKAT™ XR 和 Soleno 商业化计划的多项担忧。报告质疑了该药物的安全性、需求的可持续性以及早期处方活动的集中性。Scorpion 进一步批评 Soleno 的商业模式高度依赖单一产品，且知识产权保护预计将在不久的将来到期。报告还建议与该产品相关的某些临床研究需要进一步审查。</p>
<p>在 2025 年 8 月 15 日发布 Scorpion 报告后，Soleno 的股价经历了显著波动。在 2025 年 8 月 14 日至 2025 年 11 月 5 日期间，公司股价下降了近 40%。</p>
<p><strong>如果我购买了 Soleno 的证券怎么办？</strong> 如果您购买了 SLNO 证券并遭受损失，请立即加入我们的调查：</p>
<p>https://www.johnsonfistel.com/investigations/soleno-therapeutics-inc/</p>
<p>如需更多信息，请联系 Jim Baker，邮箱 [email protected] 或拨打 (619) 814-4471。您无需支付任何费用或承担任何义务。</p>
<p><strong>关于 Johnson Fistel, PLLP | 顶尖法律事务所，证券欺诈，投资者权益</strong> Johnson Fistel, PLLP 是一家全国知名的股东权益法律事务所，在加利福尼亚州、纽约州、乔治亚州、爱达荷州和科罗拉多州设有办事处。该事务所代表个人和机构投资者参与股东衍生诉讼和证券集体诉讼。我们还为在美国交易所购买股票的外国投资者提供服务。有关更多信息，请访问 http://www.johnsonfistel.com。</p>
<p><strong>成就</strong> 在 2024 年，Johnson Fistel 荣获 ISS 证券集体诉讼服务评选的前 10 大原告律师事务所。该事务所为投资者追回了约 90,725,000 美元的赔偿，作为首席或共同首席律师参与的案件。这是该事务所第八次被评选为美国顶尖证券律师事务所。</p>
<p>律师广告。</p>
<p>过去的结果并不保证未来的结果。</p>
<p>服务可能由我们任何办公室的律师提供。</p>
<p>Johnson Fistel, PLLP 已为本宣传沟通的传播支付费用，Frank J. Johnson 是该内容的负责律师。</p>
<p>联系方式：</p>
<p>Johnson Fistel, PLLP</p>
<p>501 W. Broadway, Suite 800, San Diego, CA 92101</p>
<p>James Baker，投资者关系或 Frank J. Johnson，律师。</p>
<p>(619) 814-4471</p>
<p>[email protected] 或 [email protected]</p>
<p>来源 Johnson Fistel, PLLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9UEgzOTgxNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQxNzIwUFJfTkVXU19VU1BSX19fX19QSDM5ODE2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9UEgzOTgxNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQxNzIwUFJfTkVXU19VU1BSX19fX19QSDM5ODE2"/></p>

Soleno治疗

<p>Johnson Fistel, PLLP 正在调查 Soleno Therapeutics, Inc. 是否存在潜在的联邦证券法违规行为。调查的重点是 Soleno 是否对 VYKAT™ XR 的商业进展和安全性做出了虚假或误导性的陈述。在 Scorpion Capital 发布了一份批评报告后，Soleno 的股价下跌了近 40%。遭受损失的股东被鼓励加入此次调查</p>

<p>, /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors violated federal securities laws by making false or misleading statements and/or failing to disclose material information to investors.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 股东权益法律事务所 Johnson Fistel, PLLP 正在调查 Soleno Therapeutics, Inc. (NASDAQ: SLNO) 或其某些高管和董事是否违反了联邦证券法，通过发布虚假或误导性声明和/或未向投资者披露重要信息。</p>
</div><p>The investigation also examines whether Soleno's public communications accurately reflected the commercial progress and safety profile of VYKAT™ XR following its regulatory approval.</p>
<div class="lb-trans"><p>该调查还审查了 Soleno 的公开沟通是否准确反映了 VYKAT™ XR 在获得监管批准后的商业进展和安全性。</p>
</div><p>In September 2025, after the FDA cleared VYKAT™ XR, Soleno highlighted to investors that the product rollout was performing strongly and surpassing internal expectations.</p>
<div class="lb-trans"><p>在 2025 年 9 月，FDA 批准 VYKAT™ XR 后，Soleno 向投资者强调该产品的推出表现强劲，超出了内部预期。</p>
</div><p>However, on Soleno's November 4, 2025 third-quarter earnings call, the company discussed challenges that emerged during the launch period, noting a slowdown in new treatment initiations and an uptick in therapy discontinuations tied to non-serious adverse events. Management also acknowledged that the launch trajectory had been affected by external commentary published earlier in the year.</p>
<div class="lb-trans"><p>然而，在 Soleno 于 2025 年 11 月 4 日的第三季度财报电话会议上，公司讨论了在推出期间出现的挑战，指出新治疗启动的放缓以及与非严重不良事件相关的治疗中断增加。管理层还承认，推出轨迹受到了年初发布的外部评论的影响。</p>
</div><p>On August 15, 2025, short seller Scorpion Capital issued a report raising a number of concerns about VYKAT™ XR and Soleno's commercialization plans. Among other assertions, the report questioned the safety profile of the drug, the sustainability of demand, and the concentration of early prescribing activity. Scorpion further criticized Soleno's business model as being highly reliant on a single product with intellectual property protection expected to mature in the near term. The report additionally suggested that certain clinical research associated with the product warranted further scrutiny.</p>
<div class="lb-trans"><p>在 2025 年 8 月 15 日，做空机构 Scorpion Capital 发布了一份报告，提出了关于 VYKAT™ XR 和 Soleno 商业化计划的多项担忧。报告质疑了该药物的安全性、需求的可持续性以及早期处方活动的集中性。Scorpion 进一步批评 Soleno 的商业模式高度依赖单一产品，且知识产权保护预计将在不久的将来到期。报告还建议与该产品相关的某些临床研究需要进一步审查。</p>
</div><p>Following the release of the Scorpion report on August 15, 2025, Soleno's stock price experienced significant volatility. Between August 14, 2025 and November 5, 2025, the Company's share price declined by nearly 40%.</p>
<div class="lb-trans"><p>在 2025 年 8 月 15 日发布 Scorpion 报告后，Soleno 的股价经历了显著波动。在 2025 年 8 月 14 日至 2025 年 11 月 5 日期间，公司股价下降了近 40%。</p>
</div><p><strong>What if I purchased Soleno securities?</strong> If you purchased SLNO securities and suffered losses, join our investigation now:</p>
<div class="lb-trans"><p><strong>如果我购买了 Soleno 的证券怎么办？</strong> 如果您购买了 SLNO 证券并遭受损失，请立即加入我们的调查：</p>
</div><p>https://www.johnsonfistel.com/investigations/soleno-therapeutics-inc/</p>
<div class="lb-trans"><p>https://www.johnsonfistel.com/investigations/soleno-therapeutics-inc/</p>
</div><p>For more information, contact Jim Baker at [email protected] or (619) 814-4471. There is no cost or obligation to you.</p>
<div class="lb-trans"><p>如需更多信息，请联系 Jim Baker，邮箱 [email protected] 或拨打 (619) 814-4471。您无需支付任何费用或承担任何义务。</p>
</div><p><strong>About Johnson Fistel, PLLP | Top Law Firm, Securities Fraud, Investors Rights</strong> Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who purchased on U.S. exchanges. For more information, please visit http://www.johnsonfistel.com.</p>
<div class="lb-trans"><p><strong>关于 Johnson Fistel, PLLP | 顶尖法律事务所，证券欺诈，投资者权益</strong> Johnson Fistel, PLLP 是一家全国知名的股东权益法律事务所，在加利福尼亚州、纽约州、乔治亚州、爱达荷州和科罗拉多州设有办事处。该事务所代表个人和机构投资者参与股东衍生诉讼和证券集体诉讼。我们还为在美国交易所购买股票的外国投资者提供服务。有关更多信息，请访问 http://www.johnsonfistel.com。</p>
</div><p><strong>Achievements</strong> In 2024, Johnson Fistel was honored to be ranked among the Top 10 Plaintiff Law Firms by the ISS Securities Class Action Services. The firm recovered approximately $90,725,000 for investors in cases where it served as lead or co-lead counsel. This marks the eighth time the firm has been recognized among the top securities law firms in the United States.</p>
<div class="lb-trans"><p><strong>成就</strong> 在 2024 年，Johnson Fistel 荣获 ISS 证券集体诉讼服务评选的前 10 大原告律师事务所。该事务所为投资者追回了约 90,725,000 美元的赔偿，作为首席或共同首席律师参与的案件。这是该事务所第八次被评选为美国顶尖证券律师事务所。</p>
</div><p>Attorney advertising.</p>
<div class="lb-trans"><p>律师广告。</p>
</div><p>Past results do not guarantee future outcomes.</p>
<div class="lb-trans"><p>过去的结果并不保证未来的结果。</p>
</div><p>Services may be performed by attorneys in any of our offices.</p>
<div class="lb-trans"><p>服务可能由我们任何办公室的律师提供。</p>
</div><p>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>
<div class="lb-trans"><p>Johnson Fistel, PLLP 已为本宣传沟通的传播支付费用，Frank J. Johnson 是该内容的负责律师。</p>
</div><p>Contact:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Johnson Fistel, PLLP</p>
<div class="lb-trans"><p>Johnson Fistel, PLLP</p>
</div><p>501 W. Broadway, Suite 800, San Diego, CA 92101</p>
<div class="lb-trans"><p>501 W. Broadway, Suite 800, San Diego, CA 92101</p>
</div><p>James Baker, Investor Relations or Frank J. Johnson, Esq.</p>
<div class="lb-trans"><p>James Baker，投资者关系或 Frank J. Johnson，律师。</p>
</div><p>(619) 814-4471</p>
<div class="lb-trans"><p>(619) 814-4471</p>
</div><p>[email protected] or [email protected]</p>
<div class="lb-trans"><p>[email protected] 或 [email protected]</p>
</div><p>SOURCE Johnson Fistel, PLLP</p>
<div class="lb-trans"><p>来源 Johnson Fistel, PLLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA0Jk5ld3NJdGVtSWQ9UEgzOTgxNiZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDQxNzIwUFJfTkVXU19VU1BSX19fX19QSDM5ODE2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=PH39816&amp;Transmission_Id=202512041720PR_NEWS_USPR_____PH39816&amp;DateId=20251204"/></p>

Johnson Fistel 开始代表 Soleno Therapeutics, Inc. (SLNO) 的股东进行调查，这些股东已经遭受了损失